KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Progyny (PGNY) Accumulated Expenses (2018 - 2025)

Progyny (PGNY) has disclosed Accumulated Expenses for 8 consecutive years, with $78.3 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses rose 6.51% to $78.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $78.3 million through Dec 2025, up 6.51% year-over-year, with the annual reading at $78.3 million for FY2025, 6.51% up from the prior year.
  • Accumulated Expenses for Q4 2025 was $78.3 million at Progyny, down from $87.4 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $91.4 million in Q1 2025, with the low at $37.4 million in Q4 2021.
  • Average Accumulated Expenses over 5 years is $62.9 million, with a median of $61.3 million recorded in 2023.
  • The sharpest move saw Accumulated Expenses surged 2705.47% in 2021, then rose 0.8% in 2022.
  • Over 5 years, Accumulated Expenses stood at $37.4 million in 2021, then surged by 34.27% to $50.2 million in 2022, then rose by 20.45% to $60.5 million in 2023, then rose by 21.49% to $73.5 million in 2024, then rose by 6.51% to $78.3 million in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $78.3 million, $87.4 million, and $79.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.